Enteric Disease Testing Market by Test Method (Biochemical Tests, Culture Methods, Immunoassays), Product Type (Consumables, Instruments, Software & Services), Pathogen, Sample Type, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Enteric Disease Testing Market was valued at USD 3.98 billion in 2024 and is projected to grow to USD 4.29 billion in 2025, with a CAGR of 8.22%, reaching USD 7.49 billion by 2032.
A strategic introduction to the enteric diagnostics ecosystem that clarifies stakeholders, operational constraints, and the evolving priorities influencing testing adoption
Enteric disease testing sits at the intersection of clinical urgency, public health surveillance and laboratory innovation. As pathogens that cause gastrointestinal illness circulate in communities and healthcare settings, the ability to detect, characterize and report infections quickly and reliably underpins outbreak response, antimicrobial stewardship, food safety monitoring and routine clinical care. This introduction frames the testing landscape by mapping the primary drivers that influence diagnostics selection and by identifying the stakeholders-laboratories, clinicians, public health agencies, manufacturers and payers-who shape demand and adoption patterns.
Technological advances have created a broader array of tools for enteric pathogen detection, from rapid immunoassays suitable for near-patient use to high-resolution sequencing platforms that reveal transmission networks. At the same time, operational realities such as sample logistics, workforce capacity and procurement cycles continue to affect which technologies are deployed and where. Regulatory pathways and quality requirements further inform development priorities and commercialization timelines. Taken together, these dynamics create a complex environment in which scientific rigor must be balanced with speed and cost-effectiveness, and where strategic planning is essential to ensure that laboratory capabilities align with public health commitments and clinical needs.
How recent technical innovations, decentralized testing, and integrated data strategies are collectively redefining enteric disease diagnostics and laboratory workflows
The last several years have seen transformative shifts in enteric disease diagnostics driven by converging advances in molecular biology, automation and data analytics. Molecular diagnostics have matured beyond single-target assays, enabling multiplexed panels and syndromic approaches that reduce time-to-result while broadening pathogen coverage. Concurrently, sequencing technologies have transitioned from research-only tools to practical instruments for surveillance and outbreak investigation, offering the granularity needed to track transmission and antimicrobial resistance patterns.
Point-of-care testing has expanded, with improved lateral flow formats and simplified amplification methods reducing reliance on centralized labs for initial triage. Automation and integrated workflows are raising throughput and consistency in clinical laboratories, while cloud-enabled data platforms are accelerating interpretation, reporting and cross-jurisdictional information exchange. These shifts are accompanied by changes in procurement behavior and partnerships across manufacturers, distributors and health systems, with more emphasis on service models and lifecycle support. As a result, stakeholders are recalibrating investment priorities to balance agility, diagnostic depth and cost containment, ensuring testing strategies are resilient to emergent pathogens and shifting public health demands.
Assessing how recent U.S. tariff changes are reshaping procurement strategies, supply chain resilience, and commercialization plans across the enteric diagnostics value chain
Policy changes affecting cross-border trade have material consequences for the enteric diagnostics supply chain and operational planning. Tariff adjustments, including measures enacted in 2025 within the United States, create a ripple effect across manufacturers, distributors and end users. Increased import costs on instruments and reagents can elevate procurement budgets and may prompt laboratory managers to re-evaluate purchasing windows, stock levels and supplier diversity. For vendors that rely on global component sourcing, tariffs heighten incentives to localize manufacturing, renegotiate supplier contracts, or absorb cost impacts through revised pricing models.
Procurement cycles elongate as organizations run scenario analyses to assess total cost of ownership under new trade conditions. Distributors and instrument manufacturers adapt by enhancing inventory buffers and expanding regional warehousing to reduce exposure to import duties. At the same time, research and development priorities may shift toward assay designs that use locally sourced components to mitigate tariff risk. These adjustments have downstream effects on timelines for deployment, testing capacity expansion and maintenance contracts. In short, trade policy changes prompt strategic rethinking across the value chain, forcing a closer alignment between sourcing strategies, risk management and customer service commitments.
Deep segmentation insights across methods, product types, end users, pathogens, sample workflows, and distribution channels to inform precision commercialization strategies
Segmentation analysis provides a granular view of where clinical and laboratory investments are concentrated and why certain technologies command attention. Based on test method, the market spans biochemical tests, culture methods, immunoassays, molecular diagnostics, and sequencing, with biochemical tests further divided into automated biochemical analysis and manual biochemical tests, culture methods split into non-selective and selective culture techniques, immunoassays differentiated by chemiluminescence immunoassay, enzyme linked immunosorbent assay and lateral flow assay, molecular diagnostics distinguished among loop mediated isothermal amplification, polymerase chain reaction and real time polymerase chain reaction, and sequencing categorized into next generation sequencing and Sanger sequencing; together these modalities form a continuum from rapid point-of-care screens to high-resolution epidemiological tools.
Based on product type, the landscape includes consumables, instruments, and software and services, with consumables further detailed as kits and reagents, instruments encompassing immuno analyzers, polymerase chain reaction instruments and sequencers, and software and services covering data analysis software and maintenance services; pricing dynamics and margin profiles differ markedly across these categories, with consumables generating recurrent revenue while instruments and software command higher upfront investment and lifecycle support obligations. Based on end user, laboratories vary across academic and clinical laboratories, diagnostic laboratories, hospitals and research institutes, each with distinct procurement processes, throughput needs and regulatory expectations that influence which products are prioritized.
Based on pathogen, testing focus encompasses bacterial pathogens, parasitic pathogens and viral pathogens, with bacterial workstreams frequently emphasizing Campylobacter, Escherichia coli and Salmonella, and viral testing often targeting adenovirus, norovirus and rotavirus; pathogen prevalence, clinical impact and surveillance priorities drive assay development and panel composition. Based on sample type, testing workflows are configured around blood samples, rectal swabs and stool samples, and each specimen class presents unique pre-analytical, biosafety and transport considerations that influence adoption of rapid versus centralized assays. Based on distribution channel, sales and fulfillment strategies pivot among direct sales, distributors and online sales, with channel choice affecting margins, customer support expectations and speed of deployment. Integrating these segmentation lenses reveals where technological investment, commercialization efforts and service models will most effectively meet clinical and public health needs.
Regional nuances in laboratory capacity, regulatory expectations, and procurement behaviors that determine the optimal positioning of diagnostic technologies across global markets
Regional dynamics shape adoption patterns and the operational footprint of enteric disease testing, driven by variations in infrastructure, regulatory regimes and disease burden. The Americas tend to concentrate laboratory capacity in a mix of centralized reference centers and hospital systems, with strong uptake of molecular methods and growing interest in sequencing for outbreak investigation; procurement cycles are influenced by large health systems and federal public health programs that prioritize interoperability and surveillance integration. Europe, Middle East & Africa display heterogeneity across countries, where Western European markets emphasize regulatory compliance, standardization and analytical depth, while parts of the Middle East and Africa prioritize scalable, robust assays and point-of-care solutions to extend diagnostic reach amid variable laboratory capacity.
Asia-Pacific presents a diverse set of markets with advanced manufacturing hubs, rapidly expanding clinical laboratory networks and substantial investments in digital health infrastructure; adoption of automated workflows, real-time PCR and next generation sequencing is accelerating in urban centers, while decentralized testing and low-cost rapid assays remain essential in lower-resource settings. Regulatory timelines, local manufacturing incentives and regional trade policies further influence where companies localize production and how they price offerings. Across regions, public health surveillance goals and healthcare financing structures determine the balance between rapid screening and comprehensive actionable diagnostics, underscoring the importance of region-specific go-to-market and partnership strategies.
How competitive focus on integrated solutions, service-driven revenue models, and strategic partnerships is shaping vendor differentiation and long-term resilience in diagnostics
Competitive dynamics in enteric diagnostics favor organizations that can combine scientific rigor with dependable supply and customer support. Leading vendors differentiate through breadth of assay menus, integration of instruments with data analytics, and comprehensive after-sales service that reduces downtime for laboratories. Strategic partnerships-whether with regional distributors, academic collaborators or public health agencies-have become critical to accelerate validation, expand access and embed technologies into surveillance networks. Companies that invest in reproducible assay performance, transparent quality systems and rapid regulatory response build trust with high-volume clinical laboratories and central reference sites.
Innovation is also complemented by business model diversification. Suppliers that offer consumable-led recurring revenue, bundled service contracts and cloud-based analytics can create stickiness with customers and stabilize revenue cycles. At the same time, entrants focused on niche diagnostics, simplified workflows or cost-effective point-of-care formats carve out positions in resource-constrained settings and urgent care contexts. Across the competitive set, resilience in sourcing, clarity around regulatory pathways and investments in training and technical support differentiate market leaders from smaller players aiming to scale.
Actionable strategic priorities for manufacturers and laboratory leaders to strengthen supply chains, accelerate adoption, and capture long-term value in enteric diagnostics
Industry leaders should adopt a multi-pronged approach that balances near-term operational stability with longer-term technology and market positioning. First, strengthen supply chain resilience by diversifying suppliers, increasing regional inventory buffers and evaluating localized manufacturing partnerships to mitigate tariff and logistics risks. Simultaneously, prioritize assays and platforms that offer flexible panel composition and scalability, enabling laboratories to respond to shifting testing needs without disruptive capital cycles. Investing in molecular multiplexing and portable amplification platforms will expand clinical utility while preserving central lab investments for high-throughput and sequencing applications.
Second, deepen engagement with end users through training programs, outcome-focused validation studies and service agreements that reduce adoption friction. Industry leaders should also invest in data integration and analytics capabilities to provide actionable insights, speed reporting and support public health integration. Third, refine commercial models to emphasize consumable-led recurring revenue, modular pricing for software and maintenance services, and tailored propositions for academic, hospital and public health customers. Finally, proactively engage with regulators and policy makers to communicate assay validation evidence and to shape guidance that expedites access while maintaining analytical rigor. These steps will position organizations to capture near-term opportunities and to lead sustainably as testing paradigms continue to evolve.
A rigorous mixed-methods research approach combining stakeholder interviews, laboratory observations, technical review, and segmentation mapping to ensure actionable and validated insights
This research synthesizes multiple evidence streams to deliver robust, reproducible conclusions. Primary data collection included structured interviews with laboratory directors, procurement officers, clinical microbiologists and public health practitioners to capture operational priorities and buyer decision criteria. Secondary analysis drew on peer-reviewed literature, regulatory filings, technical white papers and conference proceedings to map technological capabilities, validation standards and recent product clearances. Laboratory workflow observations and anonymized case studies provided real-world context on sample handling, throughput constraints and maintenance challenges.
Analytical methods combined qualitative thematic analysis with quantitative triangulation of product adoption indicators and procurement behaviors. Segmentation mapping reconciled test methods, product types, end-user profiles, pathogen focus, sample types and distribution channels to create an integrated view of demand drivers. Data quality controls included cross-validation with subject matter experts and sensitivity checks for divergent inputs. Scenario planning and risk assessments were performed to evaluate the implications of supply chain disruptions, regulatory shifts and trade policy changes, ensuring the findings remain actionable under alternative conditions.
A concise conclusion emphasizing the imperative for resilient operations, user-centric solutions, and integrated analytics to maximize public health impact
Enteric disease testing is at an inflection point where technical sophistication and operational pragmatism must coexist to meet clinical and public health imperatives. The maturation of molecular methods and sequencing augments the diagnostic toolbox, while point-of-care and simplified assays expand reach into settings with limited laboratory infrastructure. At the same time, trade policy changes and supply chain fragility reinforce the need for diversified sourcing, regional capability building and service-oriented commercial models.
Decision-makers must therefore pursue balanced strategies that accelerate adoption of high-impact technologies while safeguarding continuity of testing services. Investment in training, data integration and flexible procurement will be critical to converting technical capability into measurable public health outcomes. The conclusion is clear: the organizations that combine scientific excellence with resilient operations and close user engagement will lead the next phase of enteric diagnostics and deliver the most value to patients, laboratories and health systems.
Note: PDF & Excel + Online Access - 1 Year
A strategic introduction to the enteric diagnostics ecosystem that clarifies stakeholders, operational constraints, and the evolving priorities influencing testing adoption
Enteric disease testing sits at the intersection of clinical urgency, public health surveillance and laboratory innovation. As pathogens that cause gastrointestinal illness circulate in communities and healthcare settings, the ability to detect, characterize and report infections quickly and reliably underpins outbreak response, antimicrobial stewardship, food safety monitoring and routine clinical care. This introduction frames the testing landscape by mapping the primary drivers that influence diagnostics selection and by identifying the stakeholders-laboratories, clinicians, public health agencies, manufacturers and payers-who shape demand and adoption patterns.
Technological advances have created a broader array of tools for enteric pathogen detection, from rapid immunoassays suitable for near-patient use to high-resolution sequencing platforms that reveal transmission networks. At the same time, operational realities such as sample logistics, workforce capacity and procurement cycles continue to affect which technologies are deployed and where. Regulatory pathways and quality requirements further inform development priorities and commercialization timelines. Taken together, these dynamics create a complex environment in which scientific rigor must be balanced with speed and cost-effectiveness, and where strategic planning is essential to ensure that laboratory capabilities align with public health commitments and clinical needs.
How recent technical innovations, decentralized testing, and integrated data strategies are collectively redefining enteric disease diagnostics and laboratory workflows
The last several years have seen transformative shifts in enteric disease diagnostics driven by converging advances in molecular biology, automation and data analytics. Molecular diagnostics have matured beyond single-target assays, enabling multiplexed panels and syndromic approaches that reduce time-to-result while broadening pathogen coverage. Concurrently, sequencing technologies have transitioned from research-only tools to practical instruments for surveillance and outbreak investigation, offering the granularity needed to track transmission and antimicrobial resistance patterns.
Point-of-care testing has expanded, with improved lateral flow formats and simplified amplification methods reducing reliance on centralized labs for initial triage. Automation and integrated workflows are raising throughput and consistency in clinical laboratories, while cloud-enabled data platforms are accelerating interpretation, reporting and cross-jurisdictional information exchange. These shifts are accompanied by changes in procurement behavior and partnerships across manufacturers, distributors and health systems, with more emphasis on service models and lifecycle support. As a result, stakeholders are recalibrating investment priorities to balance agility, diagnostic depth and cost containment, ensuring testing strategies are resilient to emergent pathogens and shifting public health demands.
Assessing how recent U.S. tariff changes are reshaping procurement strategies, supply chain resilience, and commercialization plans across the enteric diagnostics value chain
Policy changes affecting cross-border trade have material consequences for the enteric diagnostics supply chain and operational planning. Tariff adjustments, including measures enacted in 2025 within the United States, create a ripple effect across manufacturers, distributors and end users. Increased import costs on instruments and reagents can elevate procurement budgets and may prompt laboratory managers to re-evaluate purchasing windows, stock levels and supplier diversity. For vendors that rely on global component sourcing, tariffs heighten incentives to localize manufacturing, renegotiate supplier contracts, or absorb cost impacts through revised pricing models.
Procurement cycles elongate as organizations run scenario analyses to assess total cost of ownership under new trade conditions. Distributors and instrument manufacturers adapt by enhancing inventory buffers and expanding regional warehousing to reduce exposure to import duties. At the same time, research and development priorities may shift toward assay designs that use locally sourced components to mitigate tariff risk. These adjustments have downstream effects on timelines for deployment, testing capacity expansion and maintenance contracts. In short, trade policy changes prompt strategic rethinking across the value chain, forcing a closer alignment between sourcing strategies, risk management and customer service commitments.
Deep segmentation insights across methods, product types, end users, pathogens, sample workflows, and distribution channels to inform precision commercialization strategies
Segmentation analysis provides a granular view of where clinical and laboratory investments are concentrated and why certain technologies command attention. Based on test method, the market spans biochemical tests, culture methods, immunoassays, molecular diagnostics, and sequencing, with biochemical tests further divided into automated biochemical analysis and manual biochemical tests, culture methods split into non-selective and selective culture techniques, immunoassays differentiated by chemiluminescence immunoassay, enzyme linked immunosorbent assay and lateral flow assay, molecular diagnostics distinguished among loop mediated isothermal amplification, polymerase chain reaction and real time polymerase chain reaction, and sequencing categorized into next generation sequencing and Sanger sequencing; together these modalities form a continuum from rapid point-of-care screens to high-resolution epidemiological tools.
Based on product type, the landscape includes consumables, instruments, and software and services, with consumables further detailed as kits and reagents, instruments encompassing immuno analyzers, polymerase chain reaction instruments and sequencers, and software and services covering data analysis software and maintenance services; pricing dynamics and margin profiles differ markedly across these categories, with consumables generating recurrent revenue while instruments and software command higher upfront investment and lifecycle support obligations. Based on end user, laboratories vary across academic and clinical laboratories, diagnostic laboratories, hospitals and research institutes, each with distinct procurement processes, throughput needs and regulatory expectations that influence which products are prioritized.
Based on pathogen, testing focus encompasses bacterial pathogens, parasitic pathogens and viral pathogens, with bacterial workstreams frequently emphasizing Campylobacter, Escherichia coli and Salmonella, and viral testing often targeting adenovirus, norovirus and rotavirus; pathogen prevalence, clinical impact and surveillance priorities drive assay development and panel composition. Based on sample type, testing workflows are configured around blood samples, rectal swabs and stool samples, and each specimen class presents unique pre-analytical, biosafety and transport considerations that influence adoption of rapid versus centralized assays. Based on distribution channel, sales and fulfillment strategies pivot among direct sales, distributors and online sales, with channel choice affecting margins, customer support expectations and speed of deployment. Integrating these segmentation lenses reveals where technological investment, commercialization efforts and service models will most effectively meet clinical and public health needs.
Regional nuances in laboratory capacity, regulatory expectations, and procurement behaviors that determine the optimal positioning of diagnostic technologies across global markets
Regional dynamics shape adoption patterns and the operational footprint of enteric disease testing, driven by variations in infrastructure, regulatory regimes and disease burden. The Americas tend to concentrate laboratory capacity in a mix of centralized reference centers and hospital systems, with strong uptake of molecular methods and growing interest in sequencing for outbreak investigation; procurement cycles are influenced by large health systems and federal public health programs that prioritize interoperability and surveillance integration. Europe, Middle East & Africa display heterogeneity across countries, where Western European markets emphasize regulatory compliance, standardization and analytical depth, while parts of the Middle East and Africa prioritize scalable, robust assays and point-of-care solutions to extend diagnostic reach amid variable laboratory capacity.
Asia-Pacific presents a diverse set of markets with advanced manufacturing hubs, rapidly expanding clinical laboratory networks and substantial investments in digital health infrastructure; adoption of automated workflows, real-time PCR and next generation sequencing is accelerating in urban centers, while decentralized testing and low-cost rapid assays remain essential in lower-resource settings. Regulatory timelines, local manufacturing incentives and regional trade policies further influence where companies localize production and how they price offerings. Across regions, public health surveillance goals and healthcare financing structures determine the balance between rapid screening and comprehensive actionable diagnostics, underscoring the importance of region-specific go-to-market and partnership strategies.
How competitive focus on integrated solutions, service-driven revenue models, and strategic partnerships is shaping vendor differentiation and long-term resilience in diagnostics
Competitive dynamics in enteric diagnostics favor organizations that can combine scientific rigor with dependable supply and customer support. Leading vendors differentiate through breadth of assay menus, integration of instruments with data analytics, and comprehensive after-sales service that reduces downtime for laboratories. Strategic partnerships-whether with regional distributors, academic collaborators or public health agencies-have become critical to accelerate validation, expand access and embed technologies into surveillance networks. Companies that invest in reproducible assay performance, transparent quality systems and rapid regulatory response build trust with high-volume clinical laboratories and central reference sites.
Innovation is also complemented by business model diversification. Suppliers that offer consumable-led recurring revenue, bundled service contracts and cloud-based analytics can create stickiness with customers and stabilize revenue cycles. At the same time, entrants focused on niche diagnostics, simplified workflows or cost-effective point-of-care formats carve out positions in resource-constrained settings and urgent care contexts. Across the competitive set, resilience in sourcing, clarity around regulatory pathways and investments in training and technical support differentiate market leaders from smaller players aiming to scale.
Actionable strategic priorities for manufacturers and laboratory leaders to strengthen supply chains, accelerate adoption, and capture long-term value in enteric diagnostics
Industry leaders should adopt a multi-pronged approach that balances near-term operational stability with longer-term technology and market positioning. First, strengthen supply chain resilience by diversifying suppliers, increasing regional inventory buffers and evaluating localized manufacturing partnerships to mitigate tariff and logistics risks. Simultaneously, prioritize assays and platforms that offer flexible panel composition and scalability, enabling laboratories to respond to shifting testing needs without disruptive capital cycles. Investing in molecular multiplexing and portable amplification platforms will expand clinical utility while preserving central lab investments for high-throughput and sequencing applications.
Second, deepen engagement with end users through training programs, outcome-focused validation studies and service agreements that reduce adoption friction. Industry leaders should also invest in data integration and analytics capabilities to provide actionable insights, speed reporting and support public health integration. Third, refine commercial models to emphasize consumable-led recurring revenue, modular pricing for software and maintenance services, and tailored propositions for academic, hospital and public health customers. Finally, proactively engage with regulators and policy makers to communicate assay validation evidence and to shape guidance that expedites access while maintaining analytical rigor. These steps will position organizations to capture near-term opportunities and to lead sustainably as testing paradigms continue to evolve.
A rigorous mixed-methods research approach combining stakeholder interviews, laboratory observations, technical review, and segmentation mapping to ensure actionable and validated insights
This research synthesizes multiple evidence streams to deliver robust, reproducible conclusions. Primary data collection included structured interviews with laboratory directors, procurement officers, clinical microbiologists and public health practitioners to capture operational priorities and buyer decision criteria. Secondary analysis drew on peer-reviewed literature, regulatory filings, technical white papers and conference proceedings to map technological capabilities, validation standards and recent product clearances. Laboratory workflow observations and anonymized case studies provided real-world context on sample handling, throughput constraints and maintenance challenges.
Analytical methods combined qualitative thematic analysis with quantitative triangulation of product adoption indicators and procurement behaviors. Segmentation mapping reconciled test methods, product types, end-user profiles, pathogen focus, sample types and distribution channels to create an integrated view of demand drivers. Data quality controls included cross-validation with subject matter experts and sensitivity checks for divergent inputs. Scenario planning and risk assessments were performed to evaluate the implications of supply chain disruptions, regulatory shifts and trade policy changes, ensuring the findings remain actionable under alternative conditions.
A concise conclusion emphasizing the imperative for resilient operations, user-centric solutions, and integrated analytics to maximize public health impact
Enteric disease testing is at an inflection point where technical sophistication and operational pragmatism must coexist to meet clinical and public health imperatives. The maturation of molecular methods and sequencing augments the diagnostic toolbox, while point-of-care and simplified assays expand reach into settings with limited laboratory infrastructure. At the same time, trade policy changes and supply chain fragility reinforce the need for diversified sourcing, regional capability building and service-oriented commercial models.
Decision-makers must therefore pursue balanced strategies that accelerate adoption of high-impact technologies while safeguarding continuity of testing services. Investment in training, data integration and flexible procurement will be critical to converting technical capability into measurable public health outcomes. The conclusion is clear: the organizations that combine scientific excellence with resilient operations and close user engagement will lead the next phase of enteric diagnostics and deliver the most value to patients, laboratories and health systems.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
199 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Expansion of multiplexed molecular panels for simultaneous detection of multiple enteric pathogens reducing diagnosis time
- 5.2. Adoption of rapid point of care immunoassays for community based detection of norovirus and rotavirus infections
- 5.3. Integration of next generation sequencing in clinical settings for comprehensive outbreak source tracking and antimicrobial resistance profiling
- 5.4. Deployment of CRISPR based diagnostic platforms for ultra sensitive detection of low abundance enteric pathogens in stool samples
- 5.5. Strategic partnerships between diagnostic manufacturers and telehealth providers to facilitate remote enteric disease testing and consultation
- 5.6. Implementation of digital stool diagnostics coupled with AI analytics for predictive modeling of enteric disease outbreaks in public health surveillance
- 5.7. Regulatory approval and commercialization of lab on a chip devices for portable multiplexed detection of bacterial viral and parasitic enteric agents
- 5.8. Rising demand for fecal microbiome testing as a complementary tool for differential diagnosis and personalized treatment of gastrointestinal infections
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Enteric Disease Testing Market, by Test Method
- 8.1. Biochemical Tests
- 8.1.1. Automated Biochemical Analysis
- 8.1.2. Manual Biochemical Tests
- 8.2. Culture Methods
- 8.2.1. Non Selective Culture
- 8.2.2. Selective Culture
- 8.3. Immunoassays
- 8.3.1. Chemiluminescence Immunoassay
- 8.3.2. Enzyme Linked Immunosorbent Assay
- 8.3.3. Lateral Flow Assay
- 8.4. Molecular Diagnostics
- 8.4.1. Loop Mediated Isothermal Amplification
- 8.4.2. Polymerase Chain Reaction
- 8.4.3. Real Time Polymerase Chain Reaction
- 8.5. Sequencing
- 8.5.1. Next Generation Sequencing
- 8.5.2. Sanger Sequencing
- 9. Enteric Disease Testing Market, by Product Type
- 9.1. Consumables
- 9.1.1. Kits
- 9.1.2. Reagents
- 9.2. Instruments
- 9.2.1. Immuno Analyzers
- 9.2.2. Polymerase Chain Reaction Instruments
- 9.2.3. Sequencers
- 9.3. Software & Services
- 9.3.1. Data Analysis Software
- 9.3.2. Maintenance Services
- 10. Enteric Disease Testing Market, by Pathogen
- 10.1. Bacterial Pathogens
- 10.1.1. Campylobacter
- 10.1.2. Escherichia Coli
- 10.1.3. Salmonella
- 10.2. Parasitic Pathogens
- 10.3. Viral Pathogens
- 10.3.1. Adenovirus
- 10.3.2. Norovirus
- 10.3.3. Rotavirus
- 11. Enteric Disease Testing Market, by Sample Type
- 11.1. Blood Samples
- 11.2. Rectal Swabs
- 11.3. Stool Samples
- 12. Enteric Disease Testing Market, by End User
- 12.1. Academic And Clinical Laboratories
- 12.2. Diagnostic Laboratories
- 12.3. Hospitals
- 12.4. Research Institutes
- 13. Enteric Disease Testing Market, by Distribution Channel
- 13.1. Direct Sales
- 13.2. Distributors
- 13.3. Online Sales
- 14. Enteric Disease Testing Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Enteric Disease Testing Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Enteric Disease Testing Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Thermo Fisher Scientific Inc.
- 17.3.2. bioMérieux SA
- 17.3.3. Abbott Laboratories
- 17.3.4. Roche Holding AG
- 17.3.5. QIAGEN N.V.
- 17.3.6. Becton, Dickinson and Company
- 17.3.7. Bio-Rad Laboratories, Inc.
- 17.3.8. Danaher Corporation
- 17.3.9. PerkinElmer, Inc.
- 17.3.10. DiaSorin S.p.A.
- 17.3.11. Eurofins Scientific SE
- 17.3.12. Merck KGaA
- 17.3.13. Neogen Corporation
- 17.3.14. 3M Company
- 17.3.15. SGS SA
- 17.3.16. Intertek Group plc
- 17.3.17. Bureau Veritas SA
- 17.3.18. ALS Limited
- 17.3.19. Quest Diagnostics Incorporated
- 17.3.20. Romer Labs Division Holding GmbH
- 17.3.21. Hardy Diagnostics
- 17.3.22. Meridian Bioscience, Inc.
- 17.3.23. Hologic, Inc.
- 17.3.24. QuidelOrtho Corporation
- 17.3.25. Siemens Healthcare Diagnostics Inc.
- 17.3.26. TechLab, Inc.
- 17.3.27. Trinity Biotech plc
- 17.3.28. Biomerica, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
